Havrix Adulto (Algeldrate, Hepatitis A Virus Antigen (Inactivated))

Havrix Adulto is indicated for the prevention of hepatitis A infection in adults and adolescents who have not been previously immunized.

• Primary prophylaxis for travelers to regions where hepatitis A is endemic.
• Post‑exposure prophylaxis for individuals with recent contact with hepatitis A cases.
• Immunization of people at occupational risk, such as laboratory workers handling hepatitis A specimens.
• Vaccination of individuals with chronic liver disease to reduce severe outcomes.
• Use in outbreak settings to quickly increase community immunity.
• Administration as part of combined hepatitis A and B vaccination schedules when appropriate.

The safety profile of Havrix Adulto reflects the typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness, or swelling at the injection site.
• Low‑grade fever lasting less than 24 hours.
• Headache or fatigue that resolves spontaneously.
• Transient muscle aches or joint discomfort.
• Nausea or mild gastrointestinal upset.
• Dizziness or feeling of light‑headedness.
• Localized itching or rash at the injection site.
• Mild swelling of lymph nodes near the injection site.
• Temporary feeling of warmth or tingling at the injection area.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face.
• Neurological events such as Guillain‑Barré syndrome, though extremely rare.
• Autoimmune phenomena such as thrombocytopenia, reported very rarely.

Before administering Havrix Adulto, healthcare providers should consider several precautionary factors to ensure safe and effective immunization.

• Verify that the patient has no known severe allergy to any vaccine component, especially gelatin or aluminum salts.
• Defer vaccination in individuals with acute moderate or severe illness until recovery.
• Assess pregnancy status; vaccination may be postponed if the risk is unclear.
• Review history of immune system disorders, as response to the vaccine may be reduced.
• Ensure proper intramuscular injection technique to minimize local reactions.
• Document previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Adulto generally has a low potential for drug interactions, but certain concomitant therapies may require attention.

Avoid

• Concurrent administration with other live viral vaccines is not recommended; separate them by at least 4 weeks.
• Use with immunoglobulin products intended for hepatitis A prophylaxis may diminish vaccine efficacy.

Use with caution

• Patients receiving immunosuppressive therapy may have a reduced antibody response; consider post‑vaccination serology.
• Anticoagulant therapy (e.g., warfarin) may increase the risk of injection‑site bruising; apply pressure after injection.
• Chronic liver disease patients should be monitored for any unexpected hepatic changes after vaccination.
• If the patient is receiving antipyretic medication, it can be given to alleviate mild fever without affecting immunogenicity.